The excitement of PPARα activation in the treatment of NAFLD subsided until recently with the emergence of selective PPARα modulators (SPPARMα), a class of compounds designed to more precisely and potently target PPARα while minimizing side effects. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.